• where experts go to learn about FDA
  • Enforcement

    • Two Synthes Inc. Execs Enter Guilty PleasJuly 22nd, 2009

      By Carmelina G. Allis – We previously reported that Synthes, Inc., Norian Corporation, and four of Synthes’s executives had been charged by the United States government for allegedly violating several provisions of Titles 18 and 21 of the United States Code.  The defendants allegedly conducted clinical …

    • United States v. Farinella: Vindicated on Appeal – It Does HappenJuly 21st, 2009

      Hyman, Phelps & McNamara’s John R. Fleder has written an article in the July/August 2009 edition of the Food and Drug Law Institute’s Update Magazine.  The article is entitled: “Vindicated on Appeal – It Does Happen.”  The article discusses a recent ruling in United States …

    • FDA Shows That It’s Serious About Food Allergen GMPsJuly 15th, 2009

      By Ricardo Carvajal –       In a complaint filed on July 1, the government is asking a federal district court to enjoin certain manufacturers of protein powder mixes and dietary supplements from further marketing of products alleged to be adulterated under FDC Act section 402(a)(4) due to the …

    • The United States Files Criminal Charges Against Orthopedic Device Manufacturers and Four ExecutivesJune 18th, 2009

      By Carmelina G. Allis – We previously reported that the State of New Jersey had entered into an agreement with Synthes, Inc. to settle allegations that the company failed to disclose financial conflicts of interest among doctors who conducted clinical testing on its products.  Now, …

    • Pet Food Business Owners Plea to FDC Act Misdemeanors in Connection with Pet Food ScandalJune 17th, 2009

      JP Ellison – The U.S. Attorney's Office for the Western District of Missouri announced three guilty pleas to misdemeanor violations of the FDC Act in connection with the "nationwide recall of pet food and the death and serious illness of countless pets across the United States …

    • Federal Judge Rejects Effort to Invoke First Amendment to Overcome Misbranding and Fraud Indictment; Holds that Press Release in Case is LabelingJune 15th, 2009

      By Jamie K. Wolszon – Earlier this month, a U.S. District Court for the Northern District of California judge refused to dismiss a criminal indictment of the former Chief Executive Officer (“CEO”) of InterMune for misbranding and wire fraud charges connected to the off-label promotion …

    • Search Warrants – What Happens When the FDA Storm ArrivesJune 1st, 2009

      The thought of federal agents storming the offices of an FDA-regulated company may seem far-fetched to some, but it is becoming a common reality, according to Hyman, Phelps & McNamara, P.C. attorneys John R. Fleder and William T. Koustas in a recent article in FDLI's Update publication. …

    • DOJ and HHS Bring the HEATMay 20th, 2009

      By JP Ellison – Today Attorney General Eric Holder and HHS Secretary Kathleen Sebelius announced the creation of a new interagency effort, the Health Care Fraud Prevention and Enforcement Action Team (HEAT), to combat healthcare fraud. Medicare appears to be the primary focus of the …

    • Federal and State Governments Intervene in Qui Tam Lawsuits against Wyeth Relating to Medicaid Best Price Reporting and Resulting Medicaid Rebate PaymentsMay 19th, 2009

      By JP Ellison –  On May 18, 2009 the U.S. Department of Justice and sixteen states announced that they had intervened in whistleblower (qui tam) lawsuits pending in federal district court in Massachusetts against  drug manufacturer Wyeth, alleging false claims act violations under federal and …

    • FDA Says Cheerios Cereal is a DrugMay 13th, 2009

      By Wes Siegner & Ricardo Carvajal –       FDA has issued a warning letter to General Mills in which the agency alleges “serious violations” of the FDC Act in the label and labeling of Cheerios cereal.  Specifically, FDA contends that the following label claims make Cheerios …

    • FDA Toughens Up on New Dietary Ingredients?May 12th, 2009

      By Ricardo Carvajal –       On May 11, FDA announced the condemnation and forfeiture of $1.3 million worth of dietary supplements marketed to body builders because the supplements contain “one or more unapproved food additives and/or new dietary ingredients for which there is inadequate information to …

    • Not the Garden State for Clinical Trials: NJ Takes on Device Manufacturer in Failure to Disclose Investigators’ Financial Stake in CompanyMay 10th, 2009

      By Christine P. Bump – The State of New Jersey announced this week that it had entered into a landmark agreement with Synthes, Inc. to settle allegations that Synthes failed to disclose financial conflicts of interest among doctors who conducted clinical testing on its products.  Synthes …

    • FDA Gets an Earful on Economically Motivated AdulterationMay 5th, 2009

      By Ricardo Carvajal –       At its public meeting on economically motivated adulteration ("EMA"), FDA got no shortage of suggestions on how to better prevent, detect, and address instances of EMA.  FDA called the meeting “to stimulate and focus discussion about ways in which the food …

    • FTC Wins Summary Judgment Against Marketer of Weight Loss ProductsApril 27th, 2009

      By Ricardo Carvajal & John R. Fleder – In Federal Trade Commission v. Medlab, Inc., the United States District Court for the Northern District of California granted summary judgment on April 21, 2009, to the FTC in an action against a marketer of weight loss products, which …

    • FTC vs. Big Food Companies – Round 2?April 20th, 2009

      By William T. Koustas – On April 20th, the Federal Trade Commission ("FTC") announced that it has brought, and at the same time tentatively settled, charges of false advertising brought under the FTC Act against Kellogg, the world’s largest cereal maker.  The FTC accused Kellogg …